Shares of Centene Corp (NYSE: CNC) surged as the insurer reaffirmed its fiscal 2025 outlook with an adjusted earnings per share (EPS) of around $1.75. This surpassed analysts' consensus of $1.69, despite previous guidance withdrawal in July due to actuarial data concerns. The company's second-quarter sales skyrocketed by 22% to $48.74 billion, well above the estimated $44.48 billion. However, the revenue growth was overshadowed by significant rises in medical costs. Centene CEO Sarah London admitted to a tough quarter and affirmed efforts to recover the earnings trajectory. A Centene executive cited by Reuters mentioned positive Medicaid performance in July. The complete article can be found on Benzinga.com.